Therapeutic advances24 Apr 2021 10:46
Is SNG001 a one trick pony ? Possibly, but not from my view. Before I continue, I raise a caveat - our clinical trials could show no benefit. However that is the roll of the dice in investment. That is why some make lots of money and others do not. There is huge risk (if you so choose). I am invested in Novacyt which recently had a crash after a massive rise and I could mention a number of others. We all have CHOICE in what we invest in.
AstraZeneca recent news : US Government invested $486m for development and supply of up to 100,000 doses and had agreement to acquire another one million doses. So far this has been upped from initial 100K doses to 700K doses.
Can see a similar RNS happening for us. Just that nobody knows the day it will be announced and volume of treatments agreed. Does anyone on this BB think agreements are not already in place with the USA Gov pending good results. These are the same GOV who have effectively sponsored us for the ACTIV-2 trial.
Fantastic news. Many types of therapies will be required for a VERY long time into the future. Stockpiling will be a critical component in many countries strategies now.
From our very own Prof Wilk and Alistair Watson
https://journals.sagepub.com/doi/full/10.1177/1753466621995050
Conclusion
COVID-19 has already caused >2.3?million deaths and has highlighted the impact and global burden of respiratory viral infections, particularly in the elderly. Although influenza is also a key respiratory pathogen, the importance of other respiratory viruses is starting to become apparent. Compared with young adults, respiratory viral infection in >65-year-olds is associated with increased morbidity and mortality. Elderly patients may present with severe lower respiratory tract infections, pneumonia or exacerbation of chronic multimorbidities. Further challenges are faced due to elderly patients often presenting without fever or respiratory symptoms but with atypical symptoms including weakness, confusion and falls. This leads to a failure in diagnosis, increased morbidity, prescription of additional medications and further nosocomial spread. It is now essential to introduce sensitive, rapid point-of-care diagnostics to identify all viruses and treat infected elderly patients. This will facilitate an understanding of the true burden of respiratory viruses. To protect the aging immune system, it is now key to couple this with the development of augmented vaccination strategies and novel anti-viral therapeutics.
SNG001 will be needed for many complications of respiratory diseases.
We all have choice with Synairgen, stay or leave. I believe the drug will be a great complement to other drugs and vaccines, not just in this pandemic, but future pandemics and helping many respiratory complication. Simple.
Sign In
Follow the stocks
